Variable effects of alpha v suppression on VEGFR-2 expression in endothelial cells of different vascular beds.
Integrins alphavbeta3 and alphavbeta5 have been long considered as proangiogenic receptors, yet genetic ablation studies demonstrated enhanced angiogenesis in mice lacking alphavbeta3 and alphavbeta5 integrins, which was attributed to increased expression of vascular endothelial growth factor receptor-2 (VEGFR-2). In this study, we determined the effect of alphavbeta3 and alphavbeta5 suppression in endothelial cells (EC) on vascular endothelial growth factor (VEGF) and VEGFR-2 expression. alphav was suppressed by shRNA in HUVEC (venous endothelial cells) and HMVEC (microvascular endothelial cells). VEGFR-2 was significantly upregulated by alphav suppression in HUVEC and downregulated in HMVEC at both mRNA and protein levels, as assessed by real-time PCR and flow cytometry, respectively. HMVEC displayed completely abolished Sp1 binding to the VEGFR-2 promoter, and HUVEC exhibited enhanced binding to the -170 E-Box element in the VEGFR-2 promoter, assessed by electrophoretic mobility shift assay. Realtime PCR also revealed opposite effects on the expression of 5 additional important genes involved in angiogenesis in the two cell types. VEGF mRNA expression was enhanced in HUVEC and reduced in HMVEC; however, these alterations were not statistically significant. VEGF-induced proliferation was upregulated in HUVEC and reduced in HMVEC following alphav suppression. No tube formation on Matrigel was observed in alphav suppressed cells, regardless of their origin. These results indicate that suppression of alphav integrins can either augment or inhibit VEGFR-2 levels and VEGF-induced proliferation in EC from different vascular beds. Hence, therapeutic antiangiogenic intervention by siRNA- mediated suppression of alphav integrins should take into account variable and potentially hazardous responses in different vascular beds.
Dardik
Rima
R
The Amalia Biron Research Institute of Thrombosis and Hemostasis, Chaim Sheba Medical Center, Israel. Rima.Dardik@sheba.health.gov.il
Livnat
Tami
T
Seligsohn
Uri
U
D002196:Capillaries / Q000166:cytology; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured / Q000187:drug effects / Q000378:metabolism; D024721:E-Box Elements; D042783:Endothelial Cells / Q000187:drug effects / Q000378:metabolism*; D005434:Flow Cytometry; D005786:Gene Expression Regulation / Q000187:drug effects / Q000502:physiology*; D055785:Gene Knockdown Techniques; D006801:Humans; D039564:Integrin alphaV / Q000235:genetics / Q000502:physiology*; D039302:Integrin alphaVbeta3 / Q000502:physiology; D009928:Organ Specificity; D016133:Polymerase Chain Reaction; D011401:Promoter Regions, Genetic; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D034741:RNA, Small Interfering / Q000494:pharmacology*; D019030:Receptors, Vitronectin / Q000502:physiology; D016329:Sp1 Transcription Factor / Q000378:metabolism; D014471:Umbilical Veins / Q000166:cytology; D042461:Vascular Endothelial Growth Factor A / Q000494:pharmacology; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000096:biosynthesis* / Q000235:genetics
D039564:Integrin alphaV; D039302:Integrin alphaVbeta3; D012333:RNA, Messenger; D034741:RNA, Small Interfering; D019030:Receptors, Vitronectin; D016329:Sp1 Transcription Factor; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C064660:integrin alphaVbeta5; D040301:Vascular Endothelial Growth Factor Receptor-2